Topline data from the REST-ON study expected in Q2 2020 DUBLIN, Ireland , March 25, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly ...
Completed enrollment for the pivotal REST-ON Phase 3 study in Q4 2019; data readout expected in Q2 2020 Raised $65 million in gross proceeds from private placement with leading biotech investment funds in February 2020 ...
We are a global pharmaceutical company, proud to be unique in our space as experts in the development and commercialization of safe, novel products that address unmet medical needs through improved dosing and by ensuring the safety and efficacy of our products and product candidates.
Whether we are seeking FDA approval of commonly used drugs, acquiring new assets or utilizing our innovative technologies to change the method of administering medication, Avadel approaches every product with the patient in mind.